Bukwang Pharmaceutical announced on the 21st that it had received approval from the Ministry of Food and Drug Safety for a phase 1 clinical trial plan for SOL-804, an anticancer drug, of its subsidiary Dynaseraputix.
SOL-804 is an improved new drug that improves the existing treatment for metastatic castration-resistant prostate cancer. Dyna Therapeutics acquired worldwide development and distribution rights from Solural Pharma in Denmark in 2016 and is exclusively developing it. Patents have also been recently registered in Europe, Japan, Eurasia, Australia and Mexico.
This clinical trial is a randomized, crossover, single-dose clinical trial to compare the safety, tolerability, and pharmacokinetic properties of SOL-804 and Zytiga.
Dyna Therapeutics expects that the drug delivery platform technology applied to SOL-804 will be widely applied to various anticancer drugs in the future, showing effects even with a small dose and reducing side effects.
Meanwhile, Dyna Therapeutics is a wholly owned subsidiary of Bukwang Pharmaceutical, which specializes in the development of new pharmaceutical formulations.
Bukwang Pharmaceutical is using SOL-804, approved for clinical trials, through its subsidiary Dyna Therapeutics.
In addition to conducting preclinical studies, it is developing a treatment for dyskinesia related to Parkinson’s disease through its subsidiary, Contera Pharma, Denmark, which is undergoing a public listing. In addition, development of immuno-oncology drugs through Jaguar, a joint venture in Singapore, and treatment for Parkinson’s disease with Oxford-Dundee University in the UK is in progress.
